Knowing that AMP-activated protein kinase (AMPK) couples p53 in cell fate decision [53] and that 6PGD ablation alters the AMPK levels in breast cancer cells [22], we can conclude that increase in p53 levels upon inhibition of 6PGD in our experimental design might occur through an AMPK dependent manner. This evidence concerns the gene TP53 and breast carcinoma.